- 1 B and T cell immune responses elicited by the BNT162b2 (Pfizer-BioNTech)
- 2 COVID-19 vaccine in nursing home residents
- 3 Ignacio Torres¹, Eliseo Albert¹, Estela Giménez¹, María Jesús Alcaraz¹, Pilar Botija²,
- 4 Paula Amat³, María José Remigia³, María José Beltrán⁴, Celia Rodado⁵, Dixie Huntley¹,
- 5 Beatriz Olea¹, and David Navarro^{1,6*}
- 6 ¹Microbiology Service, Clinic University Hospital, INCLIVA Health Research Institute,
- 7 Valencia, Spain.
- 8 ²Dirección de Atención Primaria, Departamento de Salud Clínico-Malvarrosa,
- 9 Hospital Clínico Universitario de Valencia, Valencia, Spain.
- ³Hematology Service Clinic University Hospital, INCLIVA Health Research Institute,
- 11 Valencia, Spain.
- 12 ⁴Dirección de Enfermería, Departamento de Salud Clínico-Malvarrosa, Hospital
- 13 Clínico Universitario de Valencia, Valencia, Spain.
- 14 ⁵Comisión Departamental de control de Residencias. Departamento de Salud València
- 15 Clínico Malvarrosa.
- ⁶Department of Microbiology, School of Medicine, University of Valencia, Valencia,
- 17 Spain

24

- 19 *Correspondence: David Navarro, Microbiology Service, Hospital Clínico
- 20 Universitario, Instituto de Investigación INCLIVA, Valencia, and Department of
- 21 Microbiology, University of Valencia, Valencia, Spain. Av. Blasco Ibáñez 17, 46010
- 22 Valencia, Spain. Phone: 34(96)1973500; Fax: 34(96)3864173; E-mail:
- david.navarro@uv.es.

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

49

Running title: Immunogenicity of BNT162b2 COVID-19 vaccine in nursing home residents. **ABSTRACT Objectives:** The immunogenicity of the BNT162b2 COVID-19 vaccine is understudied in elderly people with comorbidities. We assessed SARS-CoV-2-S-targeted antibody and T cell responses following full vaccination in nursing home residents (NHR). **Methods:** We recruited 60 NHR (44 female; median age, 87.5 years), of whom 10 had previously had COVID-19, and 18 healthy controls (15 female; median age, 48.5 years). Pre- and post-vaccination blood specimens were available for quantitation of total antibodies binding RBD and enumeration of SARS-CoV-2-S-reactive IFN-γ CD4⁺ and CD8⁺ T cells by flow cytometry. **Results:** The seroconversion rate in presumably SARS-CoV-2 naïve NHR (95.3%), either with or without comorbidities, was similar to controls (94.4%). A robust booster effect was documented in NHR with prior COVID-19. Plasma antibody levels were higher in convalescent NHR than in individuals across the other two groups. A large percentage of NHR had SARS-CoV-2 S-reactive IFN-γ CD8⁺ and/or CD4⁺ T cells at baseline, in contrast to healthy controls. Either CD8⁺ and/or CD4⁺ T-cell responses were documented in all control subjects after vaccination. Contrariwise, the percentage of NHR exhibiting detectable SARS-CoV-2 IFN-γ CD8⁺ or CD4⁺ T-cell responses (or both), irrespective of their baseline SARS-CoV-2 infection status, dropped consistently after vaccination. Overall, SARS-CoV-2 IFN-γ CD8⁺ and CD4⁺ T-cell responses in NHR decreased in post-vaccination specimens. 48 Conclusion: The BNT162b2 COVID-19 vaccine elicits robust SARS-CoV-2-S antibody responses in NHR. Nevertheless, the frequency and magnitude of detectable

- 50 SARS-CoV-2 IFN-γ T-cell responses after vaccination was lower in NHR compared to
- 51 controls.

- 52 **Key words:** SARS-CoV-2, BNT162b2 COVID-19 vaccine, SARS-CoV-2-S antibodies;
- 53 SARS-CoV-2-S T cells, Nursing home residents.

INTRODUCTION

- 55 The BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine, a nucleoside-modified
- 56 messenger RNA that encodes the full-length transmembrane S glycoprotein locked in its
- 57 perfusion conformation, elicits high levels of serum neutralizing antibodies (NtAb),
- 58 mainly targeting the SARS-CoV-2 receptor-binding domain (RBD), and strong TH₁-
- skewed functional CD4⁺ and CD8⁺ T cell responses in experimental models and humans
- 60 [1-4]. The efficacy of the vaccine has been shown to approach 95% in preventing severe
- 61 COVID-19 across a wide range of age groups [5]. Nevertheless, there is scarce
- 62 information as to the immunogenicity and efficacy of this vaccine in elderly people with
- 63 comorbidities and frailty [6-7], who have been prioritized for vaccination worldwide
- due to their increased risk of developing severe clinical forms of COVID-19 [8]; indeed,
- 65 this subset was underrepresented in a phase III clinical trial [5]. In this regard, data from
- 66 the BNT162b2 COVID-19 vaccine phase I trial suggested reduced lower antibody
- 67 responses in older people compared to younger participants [2]. To gain further insight
- 68 into this issue, here we assessed SARS-CoV-2-S targeted antibody and functional T cell
- 69 responses after vaccination with BNT162b2 in a cohort of nursing home residents
- 70 (NHR), most displaying one or more comorbidities, either presumably SARS-CoV-2
- 71 naïve or with documented prior SARS-CoV-2 infection.

72 MATERIAL AND METHODS

Participants and study design

74 We enrolled a total of 60 subjects (44 female) onto the study, randomly selected from 75 two NH affiliated to the Clínico-Malvarrosa Health Department, Valencia (Spain), 76 which together provide care for 226 residents. The median age of participants was 87.5 77 years (range, 53-100). As shown in Table 1, 51 subjects (84%) had one or more 78 comorbidities at enrollment (median, 4; range, 1-7). A total of 18 healthy individuals 79 (15 female) aged a median of 48.5 years (range, 27 to 60 years) with no history of 80 SARS-CoV-2 infection at baseline served as controls. Baseline blood specimens were 81 collected within one week before first vaccine dose (from January 2021 to mid February 82 2021) in both NHR and controls. Post-vaccination specimens were drawn at a median of 83 17. 5 days (range, 14-35 days) or 15 days (range, 13-35 days) after the second dose in 84 NHR and controls, respectively (from February 2021 to mid March 2021). Blood 85 specimens from participants were collected in sodium heparin tubes (Beckton 86 Dickinson, U.K. Ltd., UK). Plasma specimens were separated following centrifugation 87 and cryopreserved at -20 °C. Informed consent was obtained from participants. The 88 study was approved by the Hospital Clínico Universitario INCLIVA Research Ethics 89 Committee (February, 2021).

Immunogenicity assessment

91 Antibody assays

- 92 The following immunoassays were used in the current study: (i) Roche Elecsys® Anti-
- 93 SARS-CoV-2 S (Roche Diagnostics, Pleasanton, CA, USA), an
- 94 electrochemiluminescence sandwich immunoassay (ECLIA) that quantifies total (IgG
- 95 and IgM) antibodies directed against RBD. The assay is calibrated with the first WHO
- 96 International Standard and Reference Panel for anti-SARS-CoV-2 antibody [9]. The
- 97 limit of detection of the assay is 0.4 U/ml and its quantification range is between 0.8

and 250 U/mL; (ii) Elecsys® Anti-SARS-CoV-2 (Roche Diagnostics) a qualitative ECLIA detecting IgG and IgM antibodies against SARS-CoV-2 nucleoprotein. Both assays were run on cobas® e601 modular analyzer (Roche Diagnostics, Rotkreuz, Switzerland). Plasma specimens were further diluted (1/10) for antibody quantitation when appropriate. (iii) LIAISON® SARS-CoV-2 TrimericS IgG assay (Diasorin S.p.A, Saluggia, Italy), run on a DiaSorin LIAISON platform (DiaSorin, Stillwater, USA), which measures IgG antibodies against a trimeric S-protein antigen. Samples yielding <13 AU/ml were considered negative. Immunoassays were performed and interpreted following the instructions of the respective manufacturers. Cryopreserved plasma specimens were thawed and assayed in singlets within one month after collection. Baseline and follow-up specimens from a given participant were analyzed in the same run.

T cell immunity assay

SARS □CoV □2 □ reactive IFNγ □ producing □CD8⁺ and CD4⁺ T cells were enumerated by flow cytometry for ICS (BD Fastimmune, BD □ Beckton Dickinson and Company □ Biosciences, San Jose, CA), as previously described [10,11]. Briefly, heparinized whole blood (0.5 □ mL) was simultaneously stimulated for 6 □ h with two sets of 15 □ mer overlapping peptides (11 □ mer overlap) encompassing the SARS □CoV □ 2 Spike (S) glycoprotein (S1, 158 peptides and S2, 157 peptides) at a concentration of 1 □ μg/mL per peptide, in the presence of 1 □ μg/ml of costimulatory monoclonal antibodies (mAbs) to CD28 and CD49d. Peptide mixes were obtained from JPT peptide Technologies GmbH (Berlin, Germany). Samples mock-stimulated with phosphate □ buffered saline (PBS)/dimethyl sulfoxide and costimulatory antibodies were run in parallel. Brefeldin A (10 □ μg/mL) was added for the last 4 □ h of incubation. Blood was then lysed (BD FACS lysing solution) and frozen at −80°C until tested. On

the day of testing, stimulated blood was thawed at 37°C, washed, permeabilized (BD

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

permeabilizing solution) and stained with a combination of labeled mAbs (anti \Box IFNy \Box FITC, anti \Box CD4 \Box PE, anti \Box CD8 \Box PerCP \Box Cy5.5, and anti \Box CD3 \Box APC) for 1 □ h at room temperature. Appropriate positive (phytohemagglutinin) and isotype controls were used. Cells were then washed, resuspended in 200 □ µL of 1% paraformaldehyde in PBS, and analyzed within 2□h on an FACSCanto flow cytometer using DIVA v8 software (BD Biosciences Immunocytometry Systems, San Jose, CA). CD3⁺/CD8⁺ or CD3⁺/CD4⁺ events were gated and then analyzed for IFN □ γ production. All data were corrected for background IFN-γ production and expressed as a percentage of total CD8⁺ or CD4⁺ T cells. Representative flow cytometry plots are shown in Supplementary Figure 1. **Statistical methods** Frequency comparisons for categorical variables were carried out using the Fisher exact test. Differences between medians were compared using the Mann-Whitney U-test or the Wilcoxon test for unpaired and paired data, when appropriate. Two-sided exact Pvalues were reported. A P-value <0.05 was considered statistically significant. The analyses were performed using SPSS version 20.0 (SPSS, Chicago, IL, USA). **RESULTS** SARS-CoV-2-specific antibodies in NHR and controls No serological evidence of prior SARS-CoV-2 infection was found in 49 (83%) of the 59 NHR at baseline. Pre-vaccination plasma was not available from one patient. In addition, these subjects had been tested at least once for presence of SARS-CoV-2 RNA in nasopharyngeal specimens since the beginning of the epidemic, as a part of a local public health policy for nursing homes, systematically returning negative results. Ten

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

(17%) NHR had suffered from COVID-19, as evidenced by presence of SARS-CoV-2 S and N-specific antibodies and a history of compatible clinical picture and one or more RT-PCR positive results in nasopharyngeal specimens (convalescent NHR). Plasma collected after the second vaccine dose was available for 43 of the 49 NHR with no documented prior infection. One of the remaining six patients died before having received the second dose. Forty-one out of the 43 subjects tested positive by Roche SARS-CoV-2-S immunoassay. All but one specimen tested negative by SARS-CoV-2 N immunoassay, suggesting that one NHR had presumably contracted SARS-CoV-2 infection between the first and the second vaccine dose. Therefore, the overall seroconversion rate in this NHR group was 95.3%. Of interest, plasma specimens from NHR and controls testing negative were run with LIAISON® SARS-CoV-2 TrimericS IgG assay, also returning negative results. All 10 convalescent NHR had detectable SARS-CoV-2 S and N-binding antibodies at baseline; one patient died before receiving the second vaccine dose. A booster effect was observed in all nine individuals following full dose vaccination, with a median 33-fold (range, 10 to 600-fold) increase in antibody levels. Seventeen out of 18 controls had SARS-CoV-2 S-binding antibodies after the second vaccine dose, while none tested positive for N-specific antibodies. Accordingly, the seroconversion rate in this subgroup was 94.4%. As shown in Figure 1, plasma levels of SARS-CoV-2 S antibodies following complete vaccination were higher (P<0.01) in convalescent patients (all 2,500 IU/ml) than in presumably SARS-CoV-2 naïve NHR (median 1120 IU/ml; range, 1.08-2,500) or controls (median 2,211 IU/ml; range, 18.4-2,500). Among NHR with no documented prior infection, the seroconversion rate was comparable (P>0.99) in individuals presenting either with (33/35; 94%) or without comorbidities (9/9; 100%). Moreover, having a comorbidity did not impact significantly 172 (P=0.14) on SARS-CoV-2-S antibody levels in this population group (Supplementary 173 Figure 2). 174 SARS-CoV-2-S-specific T cells in NHR and controls 175 Analysis of pre-vaccination blood specimens revealed the presence of SARS-CoV-2 S-176 reactive IFN-γ CD8⁺ and CD4⁺ T cells in 18 (36.7%) and 30 (61.2%) of 49 naïve NHR, 177 and in 6 (60%) and 8 (80%) out of 10 infected NHR; these figures were substantially 178 lower in healthy controls (17.6% for CD8⁺ and 29% for CD4⁺ T cells) (Table 2). 179 Following the second vaccine dose, all control subjects had detectable SARS-CoV-2 S-180 reactive IFN-γ CD4⁺ T cells and 88% had both IFN-γ CD4⁺ and CD8⁺ T cells. 181 Conversely, the percentage of NHR exhibiting detectable SARS-CoV-2 IFN-γ CD8⁺ or 182 CD4⁺ T cell responses (or both), independently of their baseline SARS-CoV-2 infection 183 status, dropped consistently after vaccination (except for CD8⁺ T cells in NHR without 184 prior infection), as shown in Table 2. Both loss and de novo acquisition of detectable 185 SARS-CoV-2 IFN-y CD8⁺ or CD4⁺ T-cell responses were observed in some 186 individuals, particularly in CD8⁺ T cells. Overall, the magnitude of SARS-CoV-2 IFN-y 187 CD8⁺ or CD4⁺ T cell responses in NHR, irrespective of their SARS-CoV.2 infection 188 status, decreased consistently in post-vaccination specimens, as can be seen in Table 3. 189 The opposite was observed for healthy controls. The same differential kinetics pattern 190 between NHR and controls was noticed when individuals with detectable T cell 191 responses at baseline were analyzed separately (Figure 2). 192 Overall, the rate and magnitude of detectable SARS-CoV-2 S-reactive IFN-γ CD8⁺ and 193 CD4⁺ T cell responses following vaccination were comparable in NHR with or without 194 comorbidities (Supplementary Table 1).

DISCUSSION

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

Data on the immunogenicity of the BNT162b2 COVID-19 vaccine in elderly people with comorbidities is relatively limited. The phase I trial [2] included 12 participants aged 55-85 years and assessed only B cell immunity using a SARS-CoV-2 serum neutralization assay and RBD or S1-binding antibody assays. Slightly weaker antibody responses were reported in older people than in younger participants [2]. Brockman et al. [6] found suboptimal antibody responses after the first vaccine dose in long-term care facility residents as compared to controls. Collier et al. [7] evaluated SARS-CoV-2-S-targeted B and T cell responses elicited by multiplex particle-based flow cytometry, and T cell responses as measured by a CD3⁺ IFN-γ Fluorospot, in 50 participants with a median age of 81 years. They found comparable serum antibody neutralization titers and SARS-CoV-2 S-reactive T cell numbers in participants 80 years or above as in those under 80 following the second vaccine dose. Here, we quantified total antibodies binding SARS-CoV-2 RBD by means of an ECLIA normalized to the first WHO international standard [9], which strongly correlate with neutralizing antibody titers [12,13]. In turn, SARS-CoV-2-S-reactive IFN-γ-producing CD8⁺ and CD4⁺ T cell were enumerated using a whole blood flow cytometry assay [10,11] at a median of 2-3 weeks after the second vaccine dose. Most NHR recruited (median age, 87.5 years) had one or more comorbidities (84%), and were either with or without a SARS-CoV-2 diagnosis by serological and molecular assay prior to vaccination. The main findings of the study are summarized as follows. First, overall, the SARS-CoV-2-S seroconversion rate was similar in NHR (95.2%) and controls (94.4%), with no significant differences in median antibody levels across groups. To rule out the presence of antibodies targeting epitopes outside RBD in plasma specimens from NHR and controls testing negative, these were run with a SARS-CoV-2 TrimericS IgG assay, which also returned negative results. Second, a dramatic booster

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

effect was documented in all NHR previously infected by SARS-CoV-2; in fact, these subjects reached significantly higher antibody levels than those measured in presumably naïve NHR and controls. Third, while detectable SARS-CoV-2 S-reactive IFN-y CD8⁺ and/or CD4⁺ T-cell responses were documented in post-vaccination specimens from all control subjects, they were present in 50%-70% of NHR, depending upon the T cell subset considered and whether or not subjects had prior history of SARS-CoV-2 infection. In this context, NHR individuals with no prior documentation of SARS-CoV-2 infection appeared to display poorer post-vaccination T cell responses than convalescent NHR. Moreover, in contrast to controls, a consistent decrease in the number of SARS-CoV-2-S-reactive IFN-γ CD8⁺ and CD4⁺ T cells was noticed in post-vaccination specimens from most NHR, regardless of their SARS-CoV-2 infection status. Interpreting the T cell response data presented herein is shadowed by difficulty in ascertaining the true infection status of NHR and controls, regarding which a differential effect of the second BNT162b2 dose on T and B cell immunity was reported in COVID-19-naïve and recovered individuals, with the latter exhibiting poorer responses [14,15]. In effect, functional SARS-CoV-2-S IFN-y T cells detected in pre-vaccination specimens from NHR and controls with no evidence of prior SARS-CoV-2 infection may well have been seasonal coronavirus cross-reactive T cells, reported to be present in up to 60% (for CD4⁺ T cells) of pre-pandemic blood specimens [see 16 for review]. Circulation of seasonal coronaviruses in NH facilities and repeat exposure of residents is common over the winter season. This may account for the large percentage of NHR with no documented prior SARS-CoV-2 infection displaying T cell responses at baseline (60% for CD4⁺ T cells). Nevertheless, we cannot rule out that some of the current study participants, NHR in particular, could have been asymptomatically infected and failed to mount

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

durable antibody responses, despite robustly expanding SARS-CoV-2-specific T cells [17]. This is plausible, as several SARS-CoV-2 outbreaks were declared in both NH during 2020. Likewise, healthy controls in this study were laboratory employees or staff at the Microbiology unit, and could have been exposed and infected. Regardless of the true SARS-CoV-2 infection status of participants, NHR displayed poorer SARS-CoV-2 T-cell responses than healthy controls after vaccination. In contrast, Collier et al. [7] found no age-related differences in T-cell response after full vaccination dose, although the authors admitted they were unable to adjust for confounders such as immune suppression and comorbidities and had no information on pre-vaccination SARS-CoV-2 infection status of participants. Our findings could be partly explained by the detrimental impact of age-related immunosenescence on immune response to vaccines [18]. Nonetheless, there is biological and clinical use in elucidating whether either cross-reactive or truly specific pre-existing immunity to SARS-CoV-2 may qualitatively or quantitatively modulate vaccine-elicited T cell immune responses, and if so, how this translates into effective protection against the virus. The apparent contraction of SARS-CoV-2-S-reactive IFN-y T cells in convalescent NHR following the second vaccine dose was also observed by Camara et al. [14], who hypothesized that this second dose may functionally exhaust SARS-CoV-2-S-specific T cells. This may also apply to cross-reactive T cells. In this sense, CD4⁺ T cell responses against common cold coronaviruses (CCC) were decreased in SARS-CoV-2-infected health care workers, suggesting that exposure to SARS-CoV-2 might somehow interfere with CCC responses [19]. Whether this might also be the case following vaccination needs to be defined. Fourth, comorbidities did not appear to have a major impact on either seroconversion rate or magnitude of antibody or T-cell responses following the second vaccine dose in NHR.

The current study has several limitations that must be underlined. Firstly, the number of participants was relatively limited; second, the possibility that NHR displayed SARS-CoV-2-S-reactive T cells with functional specificities other than IFN-γ production was not explored. Additionally, a whole-blood flow cytometry assay was used to assess Tcell immunity: it is uncertain whether employing isolated peripheral blood mononuclear cells instead would increase sensitivity. Finally, no attempt was made to differentiate between truly SARS-CoV-2-specific and cross-reactive T cells, which can be accomplished according to recent reports, although this need further validation [20,21]. In summary, we were able to document robust SARS-CoV-2-S antibody responses equivalent to those of healthy controls in NHR following complete vaccination, irrespective of SARS-CoV-2 infection status and presence or absence of comorbidities. Nevertheless, our data point to differential vaccine effectivity between NHR and controls in terms of eliciting SARS-CoV-2 IFN-y T-cell responses. In this context, the potential detrimental effect of pre-existing bona fide or cross-reactive SARS-CoV-2 immunity seen in NHR merits further investigation. **ACKNOWLEDGMENTS** We are grateful to all personnel who work at NHR affiliated to the Health Department Clínico-Malvarrosa and at Clinic University Hospital, in particular those at Microbiology laboratory, for their commitment in the fight against COVID-19. Eliseo Albert holds a Juan Rodés Contract (JR20/00011) from the Health Institute Carlos III. Ignacio Torres holds a Río Hortega Contract (CM20/00090) the Health Institute Carlos III.

FINANCIAL SUPPORT

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

This work received no public or private funds.

CONFLICTS OF INTEREST

The authors declare no conflicts of interest.

297 **AUTHOR CONTRIBUTIONS**

- EA, EG, MJA, PA, MJR, IT, DH and BO: Methodology and data validation. PB, MJB,
- 299 CR: in charge of implementing public health policies to combat SARS-CoV-2 epidemic
- at NHR affiliated to the Health Department Clínico-Malvarrosa. DN: Conceptualization,
- 301 supervision, writing the original draft. All authors reviewed the original draft.

302 **REFERENCES**

- 303 1. Sahin U, Muik A, Derhovanessian E, Vogler I, Kranz LM, Vormehr M, et al.
- 304 COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses.
- 305 Nature 2020;586:594-599.
- 306 2. Walsh EE, Frenck RW Jr, Falsey AR, Kitchin N, Absalon J, Gurtman A, et al. Safety
- 307 and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. N Engl J Med
- 308 2020;383:2439-2450.
- 309 3. Vogel AB, Kanevsky I, Che Y, Swanson KA, Muik A, Vormehr M, et al. BNT162b
- 310 vaccines protect rhesus macaques from SARS-CoV-2. Nature 2021. doi:
- 311 10.1038/s41586-021-03275-y.
- 312 5. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety
- 313 and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med
- 314 2020;383:2603-2615.
- 315 6. Brockman MA, Mwimanzi F, Sang Y, Ng K, Agafitei O, Ennis S, et al. Weak
- 316 humoral immune reactivity among residents of long-term care facilities following one

- 317 dose of the BNT162b2 mRNA COVID-19 vaccine. medRxiv 2021.03.17.21253773;
- 318 doi: https://doi.org/10.1101/2021.03.17.21253773.
- 7. Collier DA, Ferreira I ATM, Datir R, Meng B, Bergamaschi L, Lim E, et al. Age-
- 320 related heterogeneity in neutralising antibody responses to SARS-CoV-2 following
- 321 BNT162b2 vaccination. medRxiv 2021; doi:
- 322 https://doi.org/10.1101/2021.02.03.21251054.
- 8. Soiza RL, Scicluna C, Thomson EC. Efficacy and safety of COVID-19 vaccines in
- 324 older people. Age Ageing 2021;50:279-283.
- 9. Mattiuzzo G, Bentley EM, Hassall M, Routley S, Richardson S, Bernasconi V, et al.
- 326 Establishment of the WHO International Standard and Reference Panel for anti-SARS-
- 327 CoV-2 antibody. WHO/BS/2020.2403, December 10, 2020.
- 328 10. Giménez E, Albert E, Torres I, Remigia MJ, Alcaraz MJ, Galindo MJ, et al. SARS-
- 329 CoV-2-reactive interferon-gamma-producing CD8+ T cells in patients hospitalized with
- 330 coronavirus disease 2019. J Med Virol 2021;93:375-382.
- 331 11. Fernández-Ruiz M, Olea B, Giménez E, Laguna-Goya R, Trujillo H, Caravaca-
- Fontán F, et al. SARS-CoV-2-Specific Cell-Mediated Immunity in Kidney Transplant
- Recipients Recovered from COVID-19. Transplantation 2021; Feb 8. doi:
- 334 10.1097/TP.0000000000003672.
- 335 12. Higgins V, Fabros A, Kulasingam V. Quantitative measurement of anti-SARS-CoV-
- 336 2 antibodies: Analytical and clinical evaluation. J Clin Microbiol 2021; JCM.03149-20.
- 337 13. Poljak M, Oštrbenk Valenčak A, Štamol T, Seme K. Head-to-head comparison of
- 338 two rapid high-throughput automated electrochemiluminescence immunoassays

- 339 targeting total antibodies to the SARS-CoV-2 nucleoprotein and spike protein receptor
- 340 binding domain. J Clin Virol 2021;137:104784.
- 341 14. Camara C, Lozano-Ojalvo D, Lopez-Granados E, Paz-Artal E, Pion M, Correa-
- Rocha R, et al. Differential effects of the second SARS-CoV-2 mRNA vaccine dose on
- 343 T cell immunity in naïve and COVID-19 recovered individuals. bioRxiv
- 344 2021.03.22.436441; doi: https://doi.org/10.1101/2021.03.22.436441.
- 345 15. Samanovic MI, Cornelius AR, Wilson JP, Karmacharya T, Gray-Gaillard SL, Allen
- JR, et al. Poor antigen-specific responses to the second BNT162b2 mRNA vaccine dose
- 347 in SARS-CoV-2-experienced individuals medRxiv 2021.02.07.21251311; doi:
- 348 https://doi.org/10.1101/2021.02.07.21251311.
- 349 16. Shrotri M, van Schalkwyk MCI, Post N, Eddy D, Huntley C, Leeman D, et al. T cell
- response to SARS-CoV-2 infection in humans: A systematic review. PLoS One 2021;
- 351 16:e0245532.
- 352 17. Sekine T, Perez-Potti A, Rivera-Ballesteros O, Strålin K, Gorin JB, Olsson A, et al.
- 353 Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild
- 354 COVID-19. Cell 2020;183:158-168.e14.
- 355 18. Pereira B, Xu XN, Akbar AN. Targeting Inflammation and Immunosenescence to
- 356 Improve Vaccine Responses in the Elderly. Front Immunol 2020;11:583019.
- 357 19. da Silva Antunes R, Pallikkuth S, Williams E, Esther DY, Mateus J, Quiambao L, et
- 358 al. Differential T cell reactivity to endemic coronaviruses and SARS-CoV-2 in
- 359 community and health care workers. J Infect Dis 2021 Apr 2:jiab176.

361

362

363

364

365

367

368

369

370

371

372

373

374

375

377

378

379

380

381

382

20. Dykema AG, Zhang B, Woldemeskel BA, Garliss CC, Cheung LS, Choudhury D, et al. Functional characterization of CD4+ T-cell receptors cross-reactive for SARS-CoV-2 and endemic coronaviruses. J Clin Invest 2021 Apr 8:146922. 21. Ogbe A, Kronsteiner B, Skelly DT, Pace M, Brown A, Adland E, et al. T cell assays differentiate clinical and subclinical SARS-CoV-2 infections from cross-reactive antiviral responses. Nat Commun 2021;12:2055. 366 FIGURE LEGENDS Figure 1. SARS-CoV-2-S plasma antibody levels as measured by Roche Elecsys® Anti-SARS-CoV-2 S immunoassay in nursing home residents (NHR) with or without documented prior SARS-CoV-2 infection and healthy controls following complete vaccination. The asterisks indicate a significant difference in antibody levels across groups (*P*<0.01). **Figure 2.** Pre- and post-vaccination SARS-CoV-2-S-reactive IFN-γ-producing CD8⁺ or CD4⁺ T-cell levels in presumably SASR-CoV-2-naïve nursing home residents (NHR) 376 (A), NHR with prior documented SARS-CoV-2 infection (B) and controls (C) with detectable CD8⁺, CD4⁺ T-cell responses or both at baseline. Supplementary Figure 1. Flow cytometry plots corresponding to representative examples of individuals either with or without detectable SARS-CoV-2-S-reactive IFNγ-producing CD8+ (upper panels) or CD4⁺ (lower panels) T cells. Heparinized whole blood was simultaneously stimulated with two sets of 15 □ mer overlapping peptides (11 □ mer overlap) encompassing the SARS □ CoV □ 2 Spike (S) glycoprotein (S1, 158

peptides and S2, 157 peptides) in the presence of 1□µg/ml of costimulatory monoclonal antibodies to CD28 and CD49d. Samples mock-stimulated with phosphate□buffered saline (PBS)/dimethyl sulfoxide and costimulatory antibodies served as negative controls. Positive (phytohemagglutinin) and isotype controls were run in parallel. Cells were analyzed on a FACSCanto flow cytometer using DIVA v8 software (BD Biosciences Immunocytometry Systems, San Jose, CA).

Supplementary Figure 2. SARS-CoV-2-S plasma antibody levels as measured by Roche Elecsys® Anti-SARS-CoV-2 S immunoassay in nursing home residents (NHR) with or without comorbidities following full dose vaccination. The *P*-value for comparison is shown.

Table 1. Baseline characteristics of nursing home residents included in the study			
Characteristic	Nursing home residents		
	no. (%)		
Sex			
Male	16 (27)		
Female	44 (73)		
Comorbidities (≥1)	51 (84)		
Hypertension	40 (77)		
Dyslipidemia	34 (65)		
Chronic heart disease	18 (35)		
Diabetes mellitus	16 (31)		
Vascular disease	14 (27)		
Cancer	10 (19)		
Chronic renal disease	10 (19)		
Chronic respiratory	0 (17)		
disease	9 (17)		
Hyperuricemia	7 (13)		
Obesity	2 (4)		

Table 2. Detection of SARS-CoV-2-S-reactive T cells in pre- and post-vaccination blood specimens from nursing home residents and controls				
	SARS-CoV-2-S IFN-γ-producing T cells in pre/post-			
	vaccination peripheral blood specimens			
Study group	No. of subjects	No. of subjects	No. of subjects	
	with detectable	with detectable	with detectable	
	CD8 ⁺ T-cell response (%)	CD4 ⁺ T-cell	CD8 ⁺ and CD4 ⁺ T-	
		response	cell responses	
Nursing home				
residents with no				
documented prior	18 (36) / 27 (54)	30 (61) / 23 (46)	17 (34) / 13 (26)	
SARS-CoV-2				
infection				
Nursing home				
residents with prior	6 (60) / 5 (50)	9 (90) / 7 (70)	6 (60) / 1 (10)	
SARS-CoV-2	6 (60) / 5 (50)	8 (80) / 7 (70)	6 (60) / 4 (40)	
infection				
Healthy controls	3 (17.6) / 15 (88)	5 (29) / 17 (100)	1 (6) / 15 (88)	

Table 3. Enumeration of SARS-CoV-2-S-reactive T cells in pre- and post-vaccination peripheral blood specimens from nursing home residents and healthy controls					
Study group	SARS-CoV-2-S IFN-γ-producing T cells in pre/post-				
	vaccination peripheral blood specimens				
	CD8+, median % (range)	CD4+, median % (range)			
Nursing home residents	1.02 (0.04-4.25)/	1.47 (0.18-5.01)/			
with no documented prior	0.36 (0.04-4.95)	0.60 (0.02-4.50)			
SARS-CoV-2 infection					
Nursing home residents	0.69 (0.19-2.25)/	2.64 (1.06-4.35)/			
with prior SARS-CoV-2	0.27 (0.02-0.76)	0.06 (0.03-0.16)			
infection					
Healthy controls	0.56 (0.06-1.72) / 1.45	0.04 (0.02-0.69) / 0.73			
	(0.24-7.33)	(0.03-3.08)			



